Novavax, Inc.
Novavax, Inc. (NVAX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · NVAX · as of Mar 31, 2025
Ownership Breakdown
282
Institutional Holders
▲ 7 vs Q4
$632.20M
Total Inst. Value
▼ $194.60M vs Q4
164.44M
Shares Outstanding
freeFloat 86.03%
98.61M
13F Shares Held
▼ 4.13M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
NVAX largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC biological products, (no diagnostic substances) | 15.67M | 9.73% | 9.73% | $100.47B | May 9, 2025 | ▼ 51.9K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 12.97M | 8.05% | 8.05% | $83.12B | May 2, 2025 | ▼ 483.4K |
SHAH CAPITAL MANAGEMENT biological products, (no diagnostic substances) | 11.13M | 6.91% | 6.91% | $71.36B | May 14, 2025 | ▼ 17.0K |
STATE STREET CORP biological products, (no diagnostic substances) | 7.04M | 4.37% | 4.37% | $45.12B | May 15, 2025 | ▼ 662.2K |
SANOFI biological products, (no diagnostic substances) | 6.88M | 4.27% | 4.27% | $44.10B | May 6, 2025 | — held |
COATUE MANAGEMENT LLC biological products, (no diagnostic substances) | 3.84M | 2.38% | 2.38% | $24.60B | May 15, 2025 | ▲ 3.84M |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 3.76M | 2.34% | 2.34% | $24.13B | May 13, 2025 | ▲ 106.3K |
D. E. SHAW & CO., INC. biological products, (no diagnostic substances) | 3.26M | 2.02% | 2.02% | $20.90B | May 15, 2025 | ▼ 2.53M |
PARK WEST ASSET MANAGEMENT LLC biological products, (no diagnostic substances) | 2.53M | 1.57% | 1.57% | $16.21B | May 15, 2025 | NEW |
MORGAN STANLEY biological products, (no diagnostic substances) | 1.98M | 1.23% | 1.23% | $12.68B | May 15, 2025 | ▼ 2.96M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
15
Increased
+7.79M shares6
New Positions
first time holders24
Decreased
−16.11M shares0
Sold Out
fully exitedNet shares change (top 50)
8.31M
+7.79M / −16.11M
Net new holders
-3
6 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
NVAX insider trading · insider activity
Source: SEC Form 4
2
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Walker Robert Edward EVP, R&D | Apr 14, 2026 | Award | 99,500 | $8.46 | $841.8K | 99.5K | Form 4 ↗ |
Walker Robert Edward EVP, R&D | Apr 14, 2026 | Award | 66,000 | — | — | 6.6K | Form 4 ↗ |
Kelly James Patrick EVP, CFO and Treasurer | Mar 7, 2026 | Tax Withhold | 5,904 | $9.98 | $58.9K | 130.6K | Form 4 ↗ |
Kelly James Patrick EVP, CFO and Treasurer | Mar 2, 2026 | Award | 194,000 | $10.11 | $1.96M | 194.0K | Form 4 ↗ |
Draghia-Akli Ruxandra EVP, Research & Development | Mar 2, 2026 | Award | 139,500 | $10.11 | $1.41M | 139.5K | Form 4 ↗ |
Casey Mark J EVP, Chief Legal Officer | Mar 2, 2026 | Award | 152,000 | $10.11 | $1.54M | 152.0K | Form 4 ↗ |
Jacobs John C President and CEO | Mar 2, 2026 | Award | 551,500 | $10.11 | $5.58M | 551.5K | Form 4 ↗ |
O'Hara Elaine EVP, Chief Strategy Officer | Mar 2, 2026 | Award | 177,500 | $10.11 | $1.79M | 177.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Novavax, Inc. (NVAX) is primarily owned by institutional investors, who hold approximately 60.0% of total shares outstanding. Company insiders own approximately 13.97%, while retail and public investors account for the remaining 26.06%.
The largest institutional shareholder of Novavax, Inc. is VANGUARD GROUP INC, holding approximately 15.67 million shares — equal to 9.73% of outstanding shares — as of March 31, 2025.
A total of 282 institutional investors currently hold NVAX stock, with a combined institutional value of approximately $632,204,068 as of the most recent 13F filing period.
Frequently asked questions
NVAX ownershipNovavax, Inc. (NVAX) is primarily owned by institutional investors, who hold approximately 60.0% of shares. The largest shareholder is VANGUARD GROUP INC with a 9.73% stake. Company insiders hold 13.97%. Data sourced from SEC Form 13F as of March 31, 2025.